Arthur M. Krieg - May 18, 2021 Form 4 Insider Report for Checkmate Pharmaceuticals, Inc. (CMPI)

Role: Chief Scientific Officer
Signature: /s/ Kleem Chaudhary, attorney-in-fact
Stock symbol: CMPI
Transactions as of: May 18, 2021
Transactions value $: $174,257
Form type: 4
Date filed: 5/19/2021, 04:15 PM
Next filing: Jun 1, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CMPI	Common Stock	Purchase	$174K	+25K	+3.21%	$6.97	805K	May 18, 2021	Direct	F1
holding	CMPI	Common Stock						68.5K	May 18, 2021	See footnote	F2
holding	CMPI	Common Stock						68.5K	May 18, 2021	See footnote	F2
holding	CMPI	Common Stock						68.5K	May 18, 2021	See footnote	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions, at prices ranging from $6.42 to $7.02 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2	The shares are held by an irrevocable trust for the Reporting Person's child. The Reporting Person serves as trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Content

The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions, at prices ranging from $6.42 to $7.02 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

The shares are held by an irrevocable trust for the Reporting Person's child. The Reporting Person serves as trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.